Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.
Microbot Medical, Inc. (NASDAQ: MBOT) is a pioneering pre-clinical medical device company focused on developing groundbreaking micro-robotic medical technologies. Established with the vision to transform minimally invasive surgeries—a fast-growing sector estimated to be close to $20 billion by 2015—Microbot Medical aims to provide cutting-edge micro-invasive technologies that assist physicians in targeting disease sites with unmatched precision. The company's innovative platforms, such as LIBERTY and the Self-Cleaning Shunt (SCS), are designed to improve surgical outcomes and the quality of life for millions of patients globally.
One of Microbot Medical's core technologies, the Virob platform, is an autonomous advancing micro-robot (AAMR) less than 1mm in diameter. This micro-robot can advance forward and backward autonomously, providing precise navigation through the body. Similarly, the LIBERTY Endovascular Robotic Surgical System aims to revolutionize endovascular procedures by eliminating the need for bulky and expensive equipment while reducing radiation exposure and physician strain.
Microbot Medical has been achieving significant milestones, including positive results from its pivotal GLP pre-clinical study and its recent Investigational Device Exemption (IDE) application to the FDA. These advancements pave the way for the company's first human clinical trials. Furthermore, the company has secured both domestic and global patents, fortifying its product portfolio and creating significant barriers to entry for competitors.
Microbot Medical is actively engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for the LIBERTY system once it receives regulatory approval. The company is committed to advancing its technologies and aims to integrate future capabilities such as remote operations, imaging integration, and AI functionalities.
Despite challenges such as the COVID-19 pandemic and recent geopolitical events in Israel, Microbot Medical continues to meet its planned timelines and milestones. The company’s operations in Israel, the USA, and other parts of the globe remain uninterrupted, and it believes it will achieve regulatory and commercial milestones as scheduled.
For further information about Microbot Medical, please visit www.microbotmedical.com.
Microbot Medical (NASDAQ: MBOT) has announced the appointment of Professor Gerry O’Sullivan to its Scientific Advisory Board, enhancing its EU presence as it prepares for human clinical trials of the LIBERTY® Robotic System. With over 25 years of experience in interventional radiology, Professor O’Sullivan brings expertise in venous disease treatments. His involvement is expected to bolster innovation and execution of commercialization strategies. This comes amid increasing global interest in the LIBERTY system, designed to address the needs of interventional radiologists.
Microbot Medical Inc. (MBOT) has expanded its Scientific Advisory Board (SAB) with the appointment of Professor Mark W. Little, a distinguished academic leader from the UK. Professor Little will collaborate with other experts to enhance the regulatory and commercialization efforts for the LIBERTY Robotic System, the first single-use endovascular robotic device. Having significant experience in interventional radiology, he has previously participated in studies on the LIBERTY system and expressed confidence in its potential impact on the market. This addition signals a strengthening of the company’s clinical expertise and reinforces its strategic goals.
Microbot Medical (Nasdaq: MBOT) announced on March 13, 2023, that Dr. Stavros Spiliopoulos has joined its Scientific Advisory Board. As an internationally recognized interventional radiologist, Dr. Spiliopoulos's expertise will bolster the company's efforts to advance the LIBERTY® Robotic System towards regulatory approval and commercialization. His extensive experience in vascular interventional radiology and numerous awards further solidify his role. The addition reflects Microbot's ongoing strategy to enhance clinical awareness and establish centers of excellence in key growth markets in Europe and the Americas.
Microbot Medical (Nasdaq: MBOT) has announced that an abstract detailing the LIBERTY Robotic System will be presented at the Israeli Conference on Robotics on March 28, 2023. Dr. Eyal Morag, the company's Chief Medical Officer, will discuss the advantages of this single-use endovascular robotic system over traditional methods, highlighting reduced physician radiation exposure and physical stress. The presentation will include findings from animal feasibility studies showcasing performance and safety metrics. The conference serves as a major event for robotics advancements across various sectors, including healthcare.
FAQ
What is the current stock price of Microbot Medical (MBOT)?
What is the market cap of Microbot Medical (MBOT)?
What is Microbot Medical, Inc.?
What is the LIBERTY Endovascular Robotic Surgical System?
What recent achievements has Microbot Medical accomplished?
What are the core technologies developed by Microbot Medical?
What is the vision of Microbot Medical?
How is Microbot Medical preparing for commercialization?
What impact do recent geopolitical events have on Microbot Medical's operations?
What is the Self-Cleaning Shunt (SCS) developed by Microbot Medical?
Who is acting as the exclusive placement agent for Microbot Medical's offering?
How can I get more information about Microbot Medical?
